Filing Flows › Pulmonx (LUNG) › Q3 2026 › vs Q3 2025
Pulmonx (LUNG) Q3 2026 vs Q3 2025 (year over year)
Pulmonx's revenue rose $1.3M (+6%) from $21.5M in Q3 2025 to $22.8M in Q3 2026.
Pulmonx, Q3 2026: revenue $22.8M (+6% year over year), operating margin -32.8%, net loss $8.4M, operating cash flow −$3.2M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $22.8M | $21.5M | $1.3M | +6% |
| Net loss | $8.4M | $14.0M | −$5.6M | -40% |
| Costs & expenses | $31.2M | $36.0M | −$4.8M | -13% |
| Operating costs | $30.3M | $35.9M | −$5.6M | -16% |
| Interest & other, net | $753K | −$564K | $1.3M | — |
| Income tax | $151K | $128K | $23K | +18% |
| Cost of revenue | $5.4M | $5.5M | −$14K | -0.3% |
| Research & development | $4.9M | $4.8M | $18K | +0.4% |
| SG&A | $20.0M | $25.6M | −$5.6M | -22% |
| Operating cash sources | $8.4M | $14.0M | −$5.6M | -40% |
| Depreciation | $200K | $300K | −$100K | -33% |
| Share-based compensation | $3.6M | $5.2M | −$1.6M | -30% |
| Working capital & other | $1.4M | $329K | $1.1M | +326% |
| Cash used in operations | $3.2M | $8.2M | −$5.0M | -61% |
| Net loss absorbed | $8.4M | $14.0M | −$5.6M | -40% |
Questions
How much did Pulmonx's revenue grow year over year in Q3 2026?
Pulmonx's revenue rose $1.3M (+6%) from $21.5M in Q3 2025 to $22.8M in Q3 2026.